DLL3 – Medxy AI

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

By MedXY 06/11/2026

This case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.

Diabetes & Endocrinology news Oncology

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

By MedXY 06/10/2026

A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.

news Oncology Specialties

Obrixtamig (BI 764532): A Promising DLL3/CD3 T-Cell Engager in Heavily Pretreated DLL3-Positive Neuroendocrine Cancers

By MedXY 09/21/2025

Phase I trial of obrixtamig, a DLL3/CD3 T-cell engager, shows tolerability and encouraging efficacy in heavily pretreated patients with DLL3-positive SCLC and neuroendocrine carcinomas, supporting further development.